Efficacy and safety of indacaterol, a new 24-hour β2- agonist, in patients with asthma: A dose-ranging study

Journal of Asthma

Volumn 45, Issue 10, 2008, Pages 887-892

  Kanniess, Frank ^a,e   Boulet, Louis Philippe ^b   Pierzchala, Wladyslaw ^c   Cameron, Ray ^d   Owen, Roger ^d   Higgins, Mark ^d  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b LAVAL UNIVERSITY   (Canada)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e KLB Healthresearch Luebeck   (Germany)

Author keywords

Asthma; Bronchodilator; Efficacy; Indacaterol

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL; INDACATEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATATION; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE CALCULATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; ECZEMA; EYELID DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HUMAN; INHALER; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; NERVOUSNESS; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PREGNANCY; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 57749189082     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900802348321     Document Type: Article

References (12)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH publication 02-3659 issued January 1995 (updated November 2007; accessed 1 December 2007). At: www.ginasthma.com.
2. National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication 07-4051. Originally printed July 1997. Revised August 2007. At: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln. pdf.
3. 2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007; 29:871-878.
4. Chuchalin AG, Tsoi AN, Richter K, Krug N, Dahl R, Luursema PB, Cameron R, Bao W, Higgins M, Woessner R, van As A. Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study. Respir Med 2007; 101:2065-2075.
5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NIH publication 02-3659 issued January 1995 (updated April 2002; accessed 29 November 2006). At: www.ginasthma.com.
6. Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiselev P, Della Cioppa G. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86:19-27.
7. 2- agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008 (in press)
8. Quebe-Fehling E, Brambilla R, Bromly CL, Fishwick K, Walters EH, Hendrick DJ. The duration of action of inhaled formoterol dry powder. Br J Clin Pract 1996; 50:446-449.
9. Sykes AP, Ayres JG. A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma. Respir Med 1990; 84:135-138.
10. Bartow RA, Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55:303-322.
11. Venables TL, Addlestone MB, Smithers AJ, Blagden MD, Weston D, Gooding, T Carr EP on behalf of the PROOF research group. A comparison of the efficacy and patient acceptability of once daily budesonide via turbohaler and twice daily fluticasone propionate via disc-inhaler at an equal daily dose of 400 μg in adult asthmatics. Br J Clin Res 1996; 7:15-32.
12. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.